Form 4: aTyr Pharma Director Timothy Coughlin Acquires 50,000 Stock Options

Director Timothy Coughlin acquired 50,000 stock options in aTyr Pharma, Inc. on May 1, 2025, according to a Form 4 filing.

Summary

• On May 1, 2025, Timothy Coughlin, a director of aTyr Pharma, Inc., acquired 50,000 stock options.
• The options have an exercise price of $3.34.
• The options vest fully on the earlier of May 1, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, contingent upon continued service on the Board of Directors.
• The options expire on May 1, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing shareholder value.

Key Dates

Keywords

aTyr Pharma, Stock Options, Director, Form 4, Beneficial Ownership, Timothy Coughlin